

Special Issue

Antimicrobial Therapy in Intensive Care Unit

Message from the Guest Editors

Antimicrobial therapy in the intensive care unit (ICU) is one of the greatest challenges of contemporary medicine. The arising therapeutic problems are more prominent in the ICU setting, where patients are more vulnerable. Newer pandemics such as COVID-19 and the resulting overuse of antibiotics are adding to the existing burden. For all the abovementioned reasons, this Special Issue seeks manuscript submissions that further our understanding on antimicrobial use in intensive care units. Authors are invited to submit manuscripts of original preclinical and clinical research as well as narrative and systematic reviews/meta-analysis within their area of interest including (but not limited) to the topics highlighted below: - Antibiotic optimization, including PK/PD; - Novel antibiotics, antifungals, and antivirals, branded or emerging; - Alternative to antibiotics approaches to prevent or tackle infections, such as antibodies, bacteriophages, vaccines, immunotherapeutics; - De-escalation; - Antibiotic stewardship, including strategies to combat antibiotic overuse and combat resistance; - Antibiotic access, antibiotic innovation; - Microbiota.

Guest Editors

Dr. Elizabeth Paramythiotou

2nd Department of Intensive Care, School of Medicine, National and Kapodistrian University of Athens, 'Attikon' Hospital, Athens, Greece

Prof. Dr. Christina Routsis

Medical School, National and Kapodistrian University of Athens, ICU Evangelismos Hospital, Athens, Greece

Dr. Antoine Andreumont

Faculté de Médecine, Université de Paris, Paris, France

Deadline for manuscript submissions

closed (30 June 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/90849

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)